Zoetis Appoints Glenn David as Acting CFO

US - Zoetis Inc. has announced that Glenn David, senior vice president of Finance Operations, has been named acting Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company’s financial management and global operations, effective immediately.
calendar icon 23 April 2014
clock icon 3 minute read

Glenn David will succeed Executive Vice President and Chief Financial Officer Richard (Rick) Passov, who will be leaving the company at the end of April.

“Glenn is a tenured, well-respected leader in our organization,” said Chief Executive Officer, Juan Ramón Alaix. “His deep financial experience and knowledge of the animal health business has been serving Zoetis well, and I have every confidence in his ability to steward our financial operations at this time.” With David in place as acting CFO, reporting to Mr Alaix, the company indicated it will commence a search process among internal and external candidates for the chief financial officer position.

Experienced and Knowledgeable Finance Leader

With more than 20 years of experience in finance and operations – including roles at Pfizer, Bankers Trust, Paine Webber and Credit Suisse – Mr David has played a key role in leading the financial operations for Zoetis since its Initial Public Offering (IPO), including financial planning, analysis and support across its 70 global markets. Most recently, Mr David has served as senior vice president of Finance Operations for Zoetis, where he had led a team of more than 300 finance professionals and played a critical role in the company’s preparation and execution of its IPO in 2013.

Before the Zoetis IPO, Mr David enjoyed a career in Finance at its former parent company, Pfizer. He served in various financial roles at Pfizer, including vice president of Global Finance for Pfizer Animal Health and vice president of Finance for the US Primary Care franchise. He also played important financial roles in Pfizer’s integrations of the Pharmacia, Wyeth and King Pharmaceuticals’ acquisitions.

Prior to joining Pfizer in 1999, Mr David gained valuable financial experience at Bankers Trust, Paine Webber and Credit Suisse. He graduated magna cum laude with a bachelor’s degree in Finance from Binghamton University, and earned his MBA in Finance/Information Technology from New York University.

In speaking of Mr Passov, Mr Alaix said: “Rick was an important member of the senior team at Zoetis, particularly during our launch as a publicly held company. He helped lay the foundation for the long-term strength and vitality of our organization and importantly, assembled a world-class financial team that will carry on with his departure. We expect Rick to provide transitional support, as needed, in the coming months, and we wish him well in his next chapter.”

© 2000 - 2023 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.